Fadi G. Haddad

Peer-Reviewed Articles

1. Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol 10(1):e24-e34, 2023. e-Pub 2022. PMID: 36402146.
2. Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, Khouri I, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Kebriaei P, Garris R, Loghavi S, Jorgensen J, Kwari M, O'Brien S, Ravandi F, Jabbour E. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol. e-Pub 2023. PMID: 36600670.
3. Bataller A, Haddad FG, Issa GC, Sasaki K, Jabbour E, Borthakur G, Ferrajoli A, Short NJ. Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring. Leuk Lymphoma:1-4. e-Pub 2023. PMID: 36657414.
4. Jabbour EJ, Sasaki K, Haddad FG, Issa GC, Garcia-Manero G, Kadia TM, Jain N, Yilmaz M, DiNardo CD, Patel KP, Kanagal-Shamanna R, Champlin R, Khouri IF, Dellasala S, Pierce SA, Kantarjian H. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol. e-Pub 2023. PMID: 36683287.
5. Senapati J, Abuasab T, Haddad FG, Ravandi F, Kadia T, DiNardo C, Daver N, Pemmaraju N, Alvarado Y, Brandt MA, Kantarjian H, Borthakur G. Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol. e-Pub 2022. PMID: 36565294.
6. Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian H. Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol, 2022. e-Pub 2022.
7. Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad FG, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD.. Contemporary outcomes in IDH-mutated AML: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol, 2022. e-Pub 2022.
8. Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, Cortes J, Konopleva M, Pemmaraju N, Alvarado Y, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver N, Short NJ, Jabbour E, Kantarjian H. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol 97(7):856-864, 2022. e-Pub 2022. PMID: 35357036.
9. Haddad F, Kantarjian H, Issa GC, Jabbour E, Sasaki K. Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia. Leuk Lymphoma 63(7):1714-1717, 2022. e-Pub 2022. PMID: 35361036.
10. Saadé MC, Gh Haddad F, Sukkarieh G, Mechleb N, Waked N. The role of funduscopy in severe thrombocytopenia: A prospective study. Transfus Clin Biol 29(2):138-140, 2022. e-Pub 2021. PMID: 34923149.
11. Jammal N, Kantarjian H, Haddad FG, Jabbour E.. Management of Acute Lymphoblastic Leukemia in Older Adults. Clin Adv Hematol Oncol, 2022. e-Pub 2022.
12. Haddad FG, Zeidan A, Daver N.. Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia. The Cancer Journal, 2022. e-Pub 2022.
13. Elias Jabbour, MD; Haddad FG; Nicholas J. Short, MD; Hagop Kantarjian, MD. Treatment of Adults with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia—From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens. JAMA Oncology, 2022. e-Pub 2022.
14. Richard-Carpentier G, Kantarjian HM, Tang G, Yin CC, Khoury JD, Issa GC, Haddad F, Jain N, Ravandi F, Short NJ, DiNardo CD, Takahashi K, Konopleva MY, Daver NG, Kadia T, Garcia-Manero G, Garris R, O'Brien S, Jabbour E. Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Adv 5(23):5415-5419, 2021. PMID: 34525185.
15. Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, Short NJ, Haddad FG, Tang Z, Patel KP, Cuglievan B, Daver N, DiNardo CD, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Konopleva M, Andreeff M, Kantarjian HM, Ravandi F. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J, 2021. e-Pub 2021.
16. Abi Karam M, Kourie HR, Jalkh N, Mehawej C, Kesrouani C, Haddad FG, Feghaly I, Chouery E, Tomb R. Molecular profiling of basal cell carcinomas in young patients. BMC Med Genomics 14(1):187, 2021. e-Pub 2021. PMID: 34284772.
17. Bou Khalil R, Kassab A, Costa G, Haddad FG, Richa S, Kattan J.. Increased psychomotor retardation and tension as short-term neuropsychiatric adverse events of immune checkpoint inhibitors: A prospective cohort study. Journal of Cancer Research and Therapeutics, 2021. e-Pub 2021.
18. Eid R, Hage S, Antonios I, Moussa R, Khoury M, Haddad FG, Kourie HR, Kesrouani C, Ghorra C, Abadjian G, Kattan J. Epidemiologic and histologic characteristics of CNS lesions: a 20-year experience of a tertiary center in Lebanon. CNS Oncol 9(2):CNS55, 2020. e-Pub 2020. PMID: 32603607.
19. Richa S, Herdane M, Dwaf A, Bou Khalil R, Haddad F, El Khoury R, Zarzour M, Kassab A, Dagher R, Brunet A, El-Hage W. Trauma exposure and PTSD prevalence among Yazidi, Christian and Muslim asylum seekers and refugees displaced to Iraqi Kurdistan. PLoS One 15(6):e0233681, 2020. e-Pub 2020. PMID: 32579560.
20. Costa J, Haddad FG, Costa G, Harb A, Eid R, Kourie HR, Helou J.. Seizures in cancer patients: a vast spectrum of etiologies. Future Neurology, 2019. e-Pub 2019.
21. El Karak F, Gh Haddad F, Eid R, Al Ghor M, El Rassy E, Ahmadieh N, Choullamy T, Halim NA, Tfayli A, Farhat F, Kattan J, Nasr F, Ghosn M, Assi HI. Lung cancer and immunotherapy: a real-life experience from second line and beyond. Future Oncol 15(26):3025-3032, 2019. e-Pub 2019. PMID: 31424958.
22. Assi T, Bakouny Z, Labaki C, El Rassy E, Khazzaka A, Jabbour R, Haddad FG, Tohme A, El Karak F, Ghosn M, Kattan J. Causes of death in older patients with cancer: Experience of a tertiary care center in Lebanon. J Geriatr Oncol 10(2):365-367, 2019. e-Pub 2018. PMID: 30391115.
23. Alkassis M, Haddad FG, Gharios J, Noun R, Chakhtoura G. Quality of Life before and after Sleeve Gastrectomy in Lebanese Population. J Obes 2019:1952538, 2019. e-Pub 2019. PMID: 31467704.
24. Rassy EE, Bakouny Z, Aoun F, Haddad FG, Sleilaty G, Assi T, Kattan J. A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer. Immunotherapy 10(8):657-663, 2018. e-Pub 2018. PMID: 29562804.
25. El Rassy E, Ghosn M, Farhat F, Bakouny Z, Assi T, Chahine G, Nasr F, Haddad FG, El Karak F, Kattan J. Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience. Breast Care (Basel) 13(2):121-125, 2018. e-Pub 2018. PMID: 29887789.
26. Kourie HR, Bakouny Z, Eid R, Haddad FG, Kattan J. The merit of tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma: a meta-analysis. Future Oncol 14(9):829-835, 2018. e-Pub 2018. PMID: 29589470.
27. Haddad FG, Kattan J, Kourie HR, El Rassy E, Assi T, Adib SM. Geriatric cancer trends in the Middle-East: Findings from Lebanese cancer projections until 2025. J Geriatr Oncol 9(2):120-123, 2018. e-Pub 2017. PMID: 28877856.
28. Chelala E, Arej N, Antoun J, Kourie HR, Zaarour K, Haddad FG, Farhat F, El Karak F, Kattan J. Central Macular Thickness Monitoring after a Taxane-Based Therapy in Visually Asymptomatic Patients. Chemotherapy 62(3):199-204, 2017. e-Pub 2017. PMID: 28351058.
29. El Karak F, El Rassy E, Naderi S, Al Ghor M, Khoury J, Haddad FG, Ghosn M, Farhat F, Kattan J, Ghorra C.. Successful ALK Targeting in Small-Cell Lung Cancer. PAJO, 2017. e-Pub 2017.
30. Haddad FG, Kourie HR, Adib SM. Trends in mammography utilization for breast cancer screening in a Middle-Eastern country: Lebanon 2005-2013. Cancer Epidemiol 39(6):819-24, 2015. e-Pub 2015. PMID: 26651440.
31. Naderi S, Ghorra C, Haddad F, Kourie HR, Rassy M, El Karak F, Ghosn M, Abadjian G, Kattan J. EGFR mutation status in Middle Eastern patients with non-squamous non-small cell lung carcinoma: A single institution experience. Cancer Epidemiol 39(6):1099-102, 2015. e-Pub 2015. PMID: 26362141.

Invited Articles

1. Haddad FG, Kantarjian H, Jabbour E. EXABS-133-ALL Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S39-S41, 2022. PMID: 36164110.
2. Haddad FG, Issa GC, Jabbour E, Yilmaz M. Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia. Expert Opin Pharmacother 23(7):751-758, 2022. e-Pub 2022. PMID: 35412404.
3. Haddad F, Zeidan A, Daver N. Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia. The Cancer Journal 28(1), 2022. e-Pub 2022.
4. Haddad FG, Short NJ. Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia?. Hematology Am Soc Hematol Educ Program 1, 2022. e-Pub 2022. PMID: 36485089.
5. Haddad F, Daver N.. Targeting CD47/SIRPα in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab. Journal of Immunotherapy and Precision Oncology 4(2), 2021. e-Pub 2021.

Other Articles

1. Jammal N, Kantarjian H, Haddad F, Jabbour E Management of Acute Lymphoblastic Leukemia in Older Adults. Clin Adv Hematol Oncol 20(3), 2022.
2. Jabbour E, Haddad F, Short N, Kantarjian H Treatment of Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Review of Evidence from Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens. Accepted for publication in JAMA Oncology, 2022.
3. Haddad FG, Chebly A, El Sett A, Kourie HR, Farra C An unusual case of chronic lymphocytic leukemia with trisomy 12 and t(14;18) and a favorable response to ibrutinib. Leuk Res Rep 15:100245, 2021. PMID: 34040960.
4. Haddad FG, Daver N. Targeting CD47/SIRPa in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab,. Journal of Immunotherapy and Precision Oncology, 2021.
5. Elkaddoum R, Haddad FG, Eid R, Kourie HR. In reply: incorporating teleoncology practices in the undergraduate medical curriculum. Future Oncol, 2021.
6. Haddad FG, Kattan C, Kattan J Should immune checkpoint inhibitors be contraindicated in lung cancer patients with latent tuberculosis?. Immunotherapy 12(11):759-762, 2020. PMID: 32517560.
7. Haddad G, Saadé MC, Eid R, Haddad FG, Kourie HR PARP inhibitors: a tsunami of indications in different malignancies. Pharmacogenomics 21(3):221-230, 2020. PMID: 31967513.
8. Chebly A, Haddad FG, Bassil J, Yammine T, Korban R, Semaan W, El Karak F, Kourie HR, Farra C A rare case of acute myeloid leukemia with t(12;19)(q13;q13). Leuk Res Rep 14:100216, 2020. PMID: 32637310.
9. Moujaess E, Haddad FG, Eid R, Kourie HR The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review. Immunotherapy 11(16):1409-1422, 2019. PMID: 31621445.
10. Hajjar AH, Eid R, Haddad FG, Kourie HR FOLFIRINOX: a new standard of care in the adjuvant setting of resectable pancreatic adenocarcinomas. Future Oncol 15(17):1947-1950, 2019. PMID: 31185748.
11. Mehanna J, Haddad FG, Eid R, Lambertini M, Kourie HR Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. Int J Womens Health 11:431-437, 2019. PMID: 31447592.
12. Kattan J, Haddad FG, Menassa-Moussa L, Kesrouani C, Daccache S, Haddad FG, Atallah D Peritoneal Tuberculosis: A Forsaken Yet Misleading Diagnosis. Case Rep Oncol Med 2019:5357049, 2019. PMID: 31781444.
13. Kourie HR, Bakouny Z, Haddad FG, Eid R, Kattan J Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present) reply. Future Oncol 14(22):2225-2227, 2018. PMID: 30064260.
14. Hobeika C, Rached G, Eid R, Haddad F, Chucri S, Kourie HR, Kattan J ALK-rearranged adenocarcinoma transformed to small-cell lung cancer: a new entity with specific prognosis and treatment?. Per Med 15(2):111-115, 2018. PMID: 29714122.
15. Saleh K, Eid R, Haddad FG, Khalife-Saleh N, Kourie HR New developments in the management of head and neck cancer - impact of pembrolizumab. Ther Clin Risk Manag 14:295-303, 2018. PMID: 29497306.
16. Haddad FGH, Yared F, Alam A, Salem C, Kattan J Dual Synchronous Metastases to Pancreas and the Breast from a Small Cell Lung Cancer: A Case Report. Case Reports and Literature Review 2(2), 2018.
17. Mehanna J, Haddad FG, Eid R, Lambertini M, Kourie HR "What is the role of HER2-specific antibody immunity in patients with HER2-positive early breast cancer receiving chemotherapy plus trastuzumab?". Translational Cancer Research 7.6, 2018.
18. El Karak F, El Rassy E, Naderi S, Al Ghor M, Khoury J, Haddad FGH, Ghosn M, Farhat F, Kattan J, Ghorra C Successful ALK Targeting in Small-Cell Lung Cancer. PAJO 10(3), 2017.
19. Ghosn M, Kourie HR, El Rassy E, Haddad FG, Hanna C, El Karak F, Nasr D Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature. World J Gastrointest Oncol 8(10):745-750, 2016. PMID: 27795814.
20. Rassy EE, Tabchi S, Haddad FG, Chebib R, Assi T, Kourie HR, Nasr F Acquired factor inhibitor in a patient with monoclonal gammopathy of undetermined significance responding to rituximab. Blood Coagul Fibrinolysis 27(7):822-824, 2016. PMID: 26626040.

Editorials

1. Zouein J, Haddad FG, Eid R, Kourie HR. The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice. Immunotherapy 14(2):155-167, 2022. PMID: 34865502.
2. Elkaddoum R, Haddad F, Eid R, Kourie HR. In reply: incorporating teleoncology practices in the undergraduate medical curriculum. Future Oncol 17(1), 2021.
3. Kourie HR, Eid R, Haddad F, Ghosn M, Sarkis DK. The future of cancer research after COVID-19 pandemic: recession?. Future Oncol 16(21):1493-1495, 2020. PMID: 32469283.
4. Haddad FG, Karam E, Moujaess E, Kourie HR. Poly-(ADP-ribose) polymerase inhibitors: paradigm shift in the first-line treatment of newly diagnosed advanced ovarian cancer. Pharmacogenomics 21(10):721-727, 2020. PMID: 32597301.
5. Elkaddoum R, Haddad FG, Eid R, Kourie HR. Telemedicine for cancer patients during COVID-19 pandemic: between threats and opportunities. Future Oncol 16(18), 2020. PMID: 32356460.
6. Akiki M, Haddad FG, Kourie HR, Khaddage A, Smayra VT. PD-L1: an unavoidable biomarker in advanced triple-negative breast cancer. Biomark Med 13(18):1539-1541, 2019. PMID: 31631684.
7. Semaan A, Haddad FG, Eid R, Kourie HR, Nemr E. Immunotherapy: last bullet in platinum refractory germ cell testicular cancer. Future Oncol 15(5):533-541, 2019. PMID: 30624089.
8. Haddad FG, Eid R, Kourie HR, Barouky E, Ghosn M. Prognostic and predictive biomarkers in nonmetastatic colorectal cancers. Future Oncol 14(21):2097-2102, 2018. PMID: 30101612.
9. Eid R, Nemr E, Haddad FG, Kourie HR, Kattan J. Do checkpoint inhibitors provide new hope for management of metastatic penile carcinoma?. Future Oncol 14(8):677-680, 2018. PMID: 29521122.
10. Eid R, Haddad FG, Kourie HR, Kattan J. Electronic patient-reported outcomes: a revolutionary strategy in cancer care. Future Oncol 13(27):2397-2399, 2017. PMID: 29121784.
11. Haddad FG, Kourie HR, Kattan J. Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives. Future Oncol 13(3):201-204, 2017. PMID: 27624407.

Abstracts

1. Haddad F, Kantarjian H, Jabbour E, Issa G, Garcia-Manero G, Ravandi F, Ferrajoli A, Kadia T, Konopleva M, Pemmaraju N, Takahashi K, Alvarado Y, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver N, Short N, Pierce S, Cortes J, Sasaki K. Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Following the Discontinuation of Tyrosine Kinase Inhibitors. ASH, 2022.
2. Haddad F, Kantarjian H, Jabbour E, Short N, Pemmaraju N, Marx K, Ravandi F, Sasaki K, Issa G. Association Between Bariatric Surgery and Outcomes in Patients with Chronic Myeloid Leukemia Treated with Oral Tyrosine Kinase Inhibitors. ASH, 2022.
3. Haddad F, Kantarjian H, Short N, Konopleva M, Jain N, Ravandi F, Daver N, Alvarado Y, Takahashi K, Garcia-Manero G, Velasquez M, Garris R, Jabbour E. A Phase II Study of Blinatumomab for the Treatment of Measurable Residual Disease-Positive B-cell Acute Lymphoblastic Leukemia. ASH, 2022.
4. Haddad F, Kantarjian H, Short N, Sasaki K, Ravandi F, Kebriaei P, Huang X, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Kadia T, Takahashi K, Daver N, Khoury J, Jorgensen J, Wang S, Khouri M, Jacob J, Garris R, O’Brien S, Jabbour E. Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. ASH, 2022.
5. Sasaki K, Jabbour E, Issa G, Naqvi K, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Burger J, Borthakur G, Pemmaraju N, Haddad F, Khoury M, Paul S, Pierce S, Cortes J, Kantarjian H. Low-dose Dasatinib 50 mg/day versus Standard-dose Dasatinib 100 mg/day as Frontline Therapy in Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis. ASH, 2022.
6. Mohamed SF, Abuasbab T, Chien K, Montalban-Bravo G, Darbaniyan F, Pierce S, Soltysiak K, Haddad F, McCall D, Cuglievan B, Jabbour E, Daver N, Kadia T, Pemmaraju N, Kantarjian H, Garcia-Manero G. Characteristics And Outcomes Of Adolescent And Young Adult (AYA) Patients With Myelodysplastic Syndrome (MDS) And Chronic Myelomonocytic Leukemia (CMML): A Single-Center Retrospective Analysis. ASH, 2022.
7. Haddad F, Jabbour E, Issa G, Garcia-Manero G, Ravandi F, Kadia T, Cortes J, Konopleva M, Pemmaraju N, Alvarado T, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver N, Short N, Kantarjian H, Sasaki K. Treatment-free Remission (TFR) in Patients With Chronic Myeloid Leukemia (CML) Following the Discontinuation of Tyrosine Kinase Inhibitors. ASCO, 2022.
8. Haddad F, Sasaki K, Abuasab T, Venugopal S, Rivera D, Bazinet A, Babakhanlou R, Kim K, Senapati J, Ong F, Desikan S, Short N, Pemmaraju N, Borthakur G, DiNardo C, Daver N, Jabbour E, Garcia-Manero G, Ravandi F, Kadia T. Outcomes of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and Hyperleukocytosis. ASCO, 2022.
9. Hammond D, Sasaki K, Geppner A, Haddad F, Mohamed S, Rivera D, Siddiqui M, Alwash Y, Ramos Perez J, Morita K, Kim K, Pierce S, Gutierrez C, Pemmaraju N, Borthakur G, Dinardo C, Ravandi F, Garcia-Manero G, Kantarjian HM, Kadia TM. Contemporary Outcomes for Adults with AML Requiring ICU Admission. ASCO, 2022.
10. Eid R, Hage S, Antonios I, Moussa R, Khoury M, Haddad F, Kourie HR, Kesrouani C, Ghorra C, Abadjian G, Kattan J. Epidemiologic and histologic characteristics of central nervous system lesions: A 20-year experience of a single institution in Lebanon. Journal of Clinical Oncology, 2022.
11. Kaddoum R, Eid R, Haddad F, Germanos M, Mehawej C, Kourie HR, Kattan J. The results of 3000 Fit: A prospective study led at Saint Joseph University of Beirut. Journal of Clinical Oncology, 2022.
12. Ajami J, Jalkh N, Moubarak G, Eid R, Haddad F, Kattan J, Ghosn M, Atallah D, Choueiry E, Kourie HR. Results of NGS panel of hereditary breast and ovarian cancer in Lebanese women. Journal of Clinical Oncology, 2022.
13. Kattan J, Haddad F, Kourie HR, Naderi S, Rassy M, Karak F, Ghosn M, Ghorra C. EGFR mutation incidence and characteristics in non-squamous lung carcinoma in the Lebanese population. Journal of Clinical Oncology, 2022.
14. Haddad F, Kantarjian H, Short N, Ravandi F, Jain N, Macaron W, Kadia T, Alvarado Y, Daver N, Borthakur G, DiNardo C, Konopleva M, Wierda W, Jacob J, Roy E, Loiselle C, Milton A, Rivera J, Garris R, Jabbour E. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in older adults with newly diagnosed B-cell acute lymphoblastic leukemia: updates from a phase II trial. EHA, 2022.
15. Haddad F, Sasaki K, Abuasab T, Venugopal S, Rivera D, Bazinet A, Babakhanlou R, Kim K, Senapati J, Ong F, Desikan S, Short N, Pemmaraju N, Borthakur G, DiNardo C, Daver N, Jabbour E, Garcia-Manero G, Ravandi F, Kadia T. Outcomes of patients with newly diagnosed acute myeloid leukemia (AML) and hyperleukocytosis. EHA, 2022.
16. Haddad F, Kantarjian H, Jabbour E, Short N, Bidikian A, Ning J, Xiao L, Pemmaraju N, Marx K, Ravandi F, Sasaki K, Issa G. Association between bariatric surgery and outcomes in patients with chronic myeloid leukemia treated with oral tyrosine kinase inhibitors. EHA, 2022.
17. Eid R, Lilly E, Haddad F, Kesserouani C, Kourie HR, Khaddage A, Moubarak M, Atallah D. Characteristics of ovarian tumors in lebanon: 20 years of experience in a lebanese tertiary center. International Journal of Gynecologic Cancer EP787, 2019.
18. Eid R, Abdo M, Zgheib G, Zeidan T, Haddad F, Khaddage A, Kourie HR, Moubarak M, Atallah D. Ovarian metastases from breast cancer: series over a 20-years period at a Lebanese tertiary care center. International Journal of Gynecologic Cancer EP221, 2019.
19. Eid R, Lilly E, Haddad F, Kesserouani C, Kourie HR, Khaddage A, Moubarak M, Atallah D. Characteristics of ovarian tumors in lebanon: 20 years of experience in a lebanese tertiary center. International Journal of Gynecologic Cancer 281, 2019.
20. Eid R, Abdo M, Zgheib G, Zeidan T, Haddad F, Khaddage A, Kourie HR, Moubarak M, Atallah D. Ovarian metastases from breast cancer: series over a 20-years period at a lebanese tertiary care center. International Journal of Gynecologic Cancer 282, 2019.

Book Chapters

1. Haddad F, Daver N. An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!. In: Adv Exp Med Biol, 2021.